MedTrace Logo

Performance Under SGLT-2-Inhibitors in Humans

NCT03422263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-10-08

No results posted yet for this study

Summary

The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the physical performance of patients with Type-II-Diabetes mellitus compared to patients under other therapy regimes. Patients shall be divided into 3 groups: I - Patients with type II diabetes mellitus under new treatment with an SGLT2-Inhibitor. II - Patients with type II diabetes mellitus without SGLT-2- Inhibitor medication. III - Patients without type II diabetes mellitus but with similar comorbidities to the previous groups.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • Berner Klinik Montana

    lead OTHER

Principal Investigators

  • Devine S Frundi, MD · Berner Klinik Montana

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422263 on ClinicalTrials.gov